Duan Bailu, Han Lintao, Ming Shuping, Li JingJing, Wang Qiong, Zhang Dongning, Tian Guangyu, Huang Fang
College of Basic Medicine, Hubei University of Chinese Medicine, Wuhan 430065, China.
Pharmacy School, Hubei University of Chinese Medicine, Wuhan 430065, China.
Evid Based Complement Alternat Med. 2020 May 17;2020:1489036. doi: 10.1155/2020/1489036. eCollection 2020.
The Fuling ()-Guizhi () herb pair (FGHP) is a commonly used traditional Chinese herbal formula with coronary heart disease (CHD) treatment potential. However, the mechanism of FGHP in the treatment of CHD was still unclear. In this study, the action targets and underlying mechanism of FGHP against CHD were successfully achieved by combined network pharmacology prediction with experimental verification. 76 common targets were screened out by overlapping the chemical-protein data of FGHP and CHD-related targets. Then, two key targets were further selected for verification by using western blot analysis after analyzing PPI, GO function, and KEGG pathway. Results indicated FGHP could alleviate CHD syndromes and regulate inflammatory responses in acute myocardial ischemia rats, and the reduction of expression of TNF- and IL-6 in myocardial tissue would be one of its possible underlying mechanisms. Our work demonstrated that network pharmacology combined with experimental verification provides a credible method to elucidate the pharmacological mechanism of FGHP against CHD.
茯苓()-桂枝()药对(FGHP)是一种具有治疗冠心病(CHD)潜力的常用中药配方。然而,FGHP治疗CHD的机制仍不清楚。在本研究中,通过网络药理学预测与实验验证相结合,成功实现了FGHP抗CHD的作用靶点和潜在机制。通过重叠FGHP的化学-蛋白质数据与CHD相关靶点,筛选出76个共同靶点。然后,在分析蛋白质-蛋白质相互作用(PPI)、基因本体(GO)功能和京都基因与基因组百科全书(KEGG)通路后,进一步选择两个关键靶点进行蛋白质印迹分析验证。结果表明,FGHP可缓解急性心肌缺血大鼠的CHD症状并调节炎症反应,心肌组织中肿瘤坏死因子(TNF-)和白细胞介素-6(IL-6)表达的降低可能是其潜在机制之一。我们的工作表明,网络药理学与实验验证相结合为阐明FGHP抗CHD的药理机制提供了一种可靠的方法。